演題抄録

一般演題(口演)

開催概要
開催回
第51回・2013年・京都
 

Efficacy of zoledronic acid in postmenopausal women with adjuvant letrozole

演題番号 : O39-6

[筆頭演者]
Shunji Takahashi:1 
[共同演者]
Takuji Iwase:1、Norio Kohno:2、Takashi Ishikawa:3、Seung Jin Kim :4、Mitsuchika Hosoda:5、Jun Horiguchi:6、Hideko Yamauchi:7、Yasuo Hozumi:8、Morihito Okada:9、Masao Fukunaga:10、Shinzaburo Noguchi:4

1:Cancer Institute Hospital, JFCR, Japan、2:Tokyo Medical Univ. Hospital, Japan、3:Yokohama City Univ. Medical Center, Japan、4:Osaka Univ. Hospital, Japan、5:Hokkaido Univ. Hospital, Japan、6:Gunma Univ. Hospital, Japan、7:St. Lukes International Hospital, Japan、8:Jichi Medical Univ. Hospital, Japan、9:Hiroshima Univ. Hospital, Japan、10:Kawasaki Medical School, Japan

 

(Background)We reported 12-month results of upfront zoledronic acid (ZOL) therapy prevented bone loss in postmenopausal Japanese women who were receiving adjuvant letrozole. But the examination in the long term of aromatase inhibitor-associated bone loss has not been proved in the Japanese or Asia women. (Methods) Postmenopausal women with hormone receptor positive early breast cancer (BC) patients receiving adjuvant letrozole were randomly assigned to receive either upfront or delayed-start ZOL (4mg intravenously every 6 months) for 5 years. The delayed group received ZOL when lumbar spine (L2-L4) BMD decreased to less than young adult mean (YAM) -2.0 S.D or when a nontraumatic fracture occurred. The primary endpoint of this study was to compare the changes in L1-L4 BMD at month 12 between the groups. Secondary endpoints, measured at other predetermined timepoints, included comparing changes in L1-L4, L2-L4 and total hip (TH) BMD and markers of bone turnover, fracture incidence, and time to disease recurrence. We report the results of 36-month interim analysis. (Results) At 36 months, mean change in L1-L4 BMD was 10.7% higher in the upfront group than in the delayed group ( 95% CI, 9.2% to 12.1%; p< 0.001 ), L2-L4 BMD was 10.9% higher ( 95% CI, 9.3% to 12.5%; p< 0.001 ), and TH BMD was 6.7% higher ( 95% CI, 5.3% to 8.1%; p< 0.001 ). The incidence of fracture was significantly decreased in the upfront group (upfront, 2 (2.0%) vs. delayed, 9 (9.3%), p=0.033). By month 36, 11 patients (11.3%) in the delayed group initiated ZOL therapy. There was no significant difference of adverse events other than fever with ZOL at the first treatment between the two groups. (Conclusion) Upfront ZOL seems to be the preferred treatment strategy versus delayed administration, as it is significantly and progressively increase BMD in postmenopausal Japanese women with early BC who were receiving adjuvant letrozole for 36 months.

キーワード

臓器別:乳腺

手法別:支持療法

前へ戻る